Fulcrum therapeutics announces recent business highlights and financial results for the first quarter 2023

― appointed alex c. sapir ceo & president, effective july 1st, 2023 ― ― on track to complete enrollment in phase 3 reach trial of losmapimod  in facioscapulohumeral muscular dystrophy (fshd) during 2h'23 ― ― active discussions continue with the u.s. food and drug administration (fda)  to resolve clinical hold for ftx-6058 in sickle cell disease (scd) ―  ― conference call and webcast scheduled for 8:00 a.m.
FULC Ratings Summary
FULC Quant Ranking